



# EHA-SfPM Precision Medicine Meeting: Bridging between functional and genomic precision medicine

## Abstract Submission Guidelines

The abstract submission guidelines of the EHA-SfPM Precision Medicine Meeting: Bridging between functional and genomic precision medicine (EHA-SfPM Precision Medicine Meeting) are intended to provide clear instructions before submitting an abstract. **You are kindly requested to carefully read the guidelines stated below.**

The EHA, SfPM and the Scientific Program Committee (SPC) of the EHA-SfPM Precision Medicine Meeting maintain the right to reject any abstract that does not meet the requirements below.

## Table of Contents

Key dates .....	2
Terms & conditions .....	2
Applicable law and jurisdiction .....	2
Submission guidelines .....	3
Topics.....	3
Submission specifications.....	3
Abstract review, selection and publication.....	4



## Key dates

<b>March 7, 2024</b>	Start abstract submission
<b>July 5, 2024 (23:59 CEST)</b>	Deadline abstract submission ( <i>extended</i> )
<b>July 18, 2024</b>	Notification of allocation to authors
<b>August 9, 2024 (23:59 CEST)</b>	Withdrawal deadline

The deadline for abstract submission has been extended to **July 5, 2024 (23:59 CEST)**, submissions received after this deadline will not be considered.

## Terms & conditions

1. The SPC encourages the submission of original scientific material unpublished at the time of the abstract submission deadline:
  - a. Abstracts submitted to regional or national hematology meetings can be submitted to the EHA-SfPM Precision Medicine Meeting for inclusion in the program;
  - b. Abstracts submitted to large international meetings which are organized in the same period as the EHA-SfPM Precision Medicine Meeting (August – October 2024) are allowed to be submitted to the meeting.
  - c. Abstracts submitted to other large international meetings may also be submitted providing a clear indication about significant novel or updated information included in the appropriate abstract submission field.
2. Authors of submitted abstracts shall be the sole and exclusive owner of the abstract and all associated intellectual property rights. By submitting the abstract to EHA, the author grants EHA the right to use and (commercial) reprint the abstract in relation to the EHA-SfPM Precision Medicine Meeting. Authors of submitted abstracts understand and agree that EHA will not pay compensation for this license.
3. Authors of submitted abstracts guarantee that the abstract (and all associated intellectual property rights) is free of any third-party rights to the fullest extent permitted by law, including but not limited to, inventor's rights of remuneration and any other ancillary rights.
4. By submitting an abstract, the submitting author confirms that they have approval from all the co-authors to submit and use the data in the abstract.
5. Submitted abstracts are considered embargoed from the time of submission. The embargo is lifted at the start of the meeting.
6. Please do not submit the same study in multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
7. Similarly, abstracts or (close) copies, may not be submitted under more than 1 (one) category.

## Applicable law and jurisdiction

The above Terms and conditions are governed by the laws of the Netherlands. Any dispute related to these terms and conditions and the use or publication of the abstract shall be exclusively submitted to the district court in the Hague, the Netherlands.



## Submission guidelines

The submitted abstracts should fully adhere to the guidelines below.

1. Abstracts should be submitted in clear (American) English to allow the reviewers to focus on the scientific content of the abstract. Non-English-speaking authors are encouraged to have their abstract checked for grammar and spelling.
2. The SPC assumes all presenting authors have proficiency in English, thus are able to present and respond to questions.
3. In clinical studies, please state whether informed consent was obtained from patients.
4. The title and text may not contain trade names. The SPC reserves the right to replace trade names in accepted abstracts.
5. If off label use of drugs was involved, please state this clearly.
6. Withdrawal policy: If authors wish to withdraw their abstracts from presentation or publication, they are requested to send a letter via e-mail to the EHA Executive Office ([scientificmeetings@ehaweb.org](mailto:scientificmeetings@ehaweb.org)) before **August 9, 2024**. Consequently, the abstract will not be presented nor published.

## Topics

Please select the most appropriate topic during the abstract submission:

1. Precision medicine trials
2. Biomarkers/diagnostics with therapeutic impact
3. Data sharing/harmonization
4. Addressing intra-patient heterogeneity in diagnosis, treatment and disease monitoring
5. Next generation approaches to precision medicine
6. Precision medicine in the context of rare and ultra-rare tumors
7. Identification of combination therapies
8. Next-generation genomic precision medicine
9. Immunotherapy - Predicting responses
10. Models for functional precision medicine
11. Measurable residual disease monitoring
12. AI for precision medicine

## Submission specifications

- Title count: max. 300 characters incl. space.
- Character limit: 3500 characters (incl. spaces & punctuation / excl. headers in the template).
- Please use the following subheadings: Background / Aims / Methods / Results / Summary - Conclusion
- Images have to be submitted as JPEG, tif, or gif files:



- Due to limited space, only a simple graph/image can be submitted.
- Images and graphs should reproduce well in black and white.
- Image file should not exceed 500KB.
- Authors: There is no limit to the number of authors.
- References are obligatory when submitting an abstract

### **Abstract review, selection and publication**

1. All submitted abstracts will be reviewed by members of the Scientific Program Committee and selected faculty of the EHA-SfPM Precision Medicine Meeting.
2. Abstracts may be selected for:
  - a. oral presentation
  - b. poster presentation
  - c. rejection
3. Only the submitting author will receive a confirmation letter of acceptance for oral presentation, poster presentation, or a notice of rejection, by e-mail by **July 18, 2024**.
4. Authors of abstracts selected for an oral presentation or a poster presentation will be informed about the date of the session and presentation guidelines will be provided.
5. Oral and poster abstract presenters will need to register themselves in order to present their abstracts in the EHA-SfPM Precision Medicine Meeting.